Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study

Fig. 6

Observed percentage work impairment of patients receiving UST or TNFi by achievement of effectiveness endpoints. a cDAPSA LDA/remission; b MDA; c VLDA; achievement of effectiveness endpoints represented by yes—target achieved, or no—target not achieved. Error bars represent 95% CIs. Work impairment due to PsA is calculated for employed patients only, calculated by work time lost due to absenteeism plus presenteeism, expressed as a percentage. Abbreviations: cDAPSA, Clinical Disease Activity Index for Psoriatic Arthritis; CI, confidence interval; LDA, low disease activity; MDA, minimal disease activity; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab; VLDA, very low disease activity

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us